Drugs / CT-P27
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03511066 | Dec 2016 → Mar 2018 | influenza | Celltrion | Terminated | No outcome recorded |
| Phase 2 | NCT02071914 | Feb → May 2014 | influenza | Celltrion | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2016-10-12 | Celltrion | Regulatory Celltrion started clinical trial phase 2b for comprehensive influenza antibody new drug CT-P27 celltrion.com ↗
Celltrion announced today that it has received approval by the Korean Ministry of Food and Drug Safety (MFDS) for the Phase 2b clinical trial of CT-P27, a comprehensive influenza antibody drug under development. |
| 2013-11-20 | Celltrion | Results Celltrion announces positive data from phase 1 trial of a novel therapeutic antibody CT-P27. celltrion.com ↗
Celltrion announced positive clinical trial phase 1 data of CT-P27. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2016-10-12 | Celltrion | Celltrion started clinical trial phase 2b for comprehensive influenza antibody new drug CT-P27 celltrion.com ↗ |
| 2013-11-20 | Celltrion | Celltrion announces positive data from phase 1 trial of a novel therapeutic antibody CT-P27. celltrion.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT-P27 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02071914 ↗ |
| Route | Intravenous | “CT-P27 will be administrated once in IV infusion.” NCT02071914 ↗ |